Prognostic significance of high phosphatase of regenerating liver-3 expression in patients with gastric cancer who underwent curative gastrectomy

Digestive Diseases and Sciences

Volumn 57, Issue 6, 2012, Pages 1568-1575

  Bilici, Ahmet ^a,b   Ustaalioglu, Bala Basak Oven ^a   Yavuzer, Dilek ^a   Seker, Mesut ^a   Mayadagli, Alpaslan ^a   Gumus, Mahmut ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Menderes Mah   (Turkey)

Author keywords

Gastric cancer; Lymph node metastasis; PRL 3 expression; Prognosis; Recurrence

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MOLECULAR MARKER; PHOSPHATASE OF REGENERATING LIVER 3 PROTEIN; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN TYROSINE PHOSPHATASES; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84864279284     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2076-9     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 20 years. Gastric Cancer. 2004;7:196-201.
3. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362: 305-315. (Pubitemid 36936845)
4. Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458-1468. (Pubitemid 46945355)
5. Kim JG, Sohn SK, Chae YS, Cho YY, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007;18:1030-1036. (Pubitemid 47050494)
6. Lyon MA, Ducruet AP, Wipf P, Lazo JS. Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov. 2002;1:961-976. (Pubitemid 37361602)
7. Cates CA, Michael RL, Stayrook KR, et al. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett. 1996;110:49-55. (Pubitemid 27042920)
8. Zeng Q, Hong W, Tan YH. Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun. 1998;244:421-427. (Pubitemid 28414098)
9. Marx J. Cancer research. New insights into metastasis. Science. 2001;294:281-282. (Pubitemid 32963373)
10. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science. 2001;294: 1343-1346. (Pubitemid 33063101)
11. Bardelli A, Saha S, Sager JA, et al. PRL-3 expression in metastatic cancers. Clin Cancer Res. 2003;9:5607-5615. (Pubitemid 37499481)
12. Peng L, Ning J, Meng L, Shou C. The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol. 2004;130:521-526. (Pubitemid 39149883)
13. Kato H, Semba S, Miskad UA, et al. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res. 2004;10:7318-7328. (Pubitemid 39487721)
14. Radke I, Götte M, Kersting C, et al. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer. 2006;95:347-354. (Pubitemid 44187596)
15. Wang L, Peng L, Dong B, et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol. 2006;17:1517-1522. (Pubitemid 44542037)
16. Ren T, Jiang B, Xing X, et al. Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer. Pathol Oncol Res. 2009;15:555-560.
17. Molleví DG, Aytes A, Padullés L, et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer. 2008;99:1718-1725.
18. Al-Aidaroos AQ, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem. 2010;111:1087-1098.
19. Miskad UA, Semba S, Kato H, Yokozaki H. Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology. 2004;71:176-184. (Pubitemid 38969875)
20. Miskad UA, Semba S, Kato H, et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch. 2007;450:303-310. (Pubitemid 46376561)
21. Li ZR, Wang Z, Zhu BH, et al. Association of tyrosine PRL-3 phosphatase protein expression with peritoneal metastasis of gastric carcinoma and prognosis. Surg Today. 2007;37:646-651. (Pubitemid 47101246)
22. Wang Z, He YL, Cai SR, et al. Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int J Cancer. 2008;123:1439-1447.
23. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. New York: Springer; 2010:117.
24. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer. 1998; 1:10-24.
25. Zhang ZY, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. Pharmacol Ther. 2002;93:307-317. (Pubitemid 34615571)
26. Stephens B, Han H, Hostetter G, et al. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther. 2008;7:202-210.
27. Guzińska-Ustymowicz K, Pryczynicz A. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anticancer Agents Med Chem. 2011;11:99-108.
28. Dai N, Lu AP, Shou CC, Li JY. Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer. World J Gastroenterol. 2009;15:1499-1505.
29. Ooki A, Yamashita K, Kikuchi S, et al. Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer. Oncol Rep. 2009;21:1467-1475.
30. Wang Z, Cai SR, He YL, et al. High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients. Ann Surg Oncol. 2009;16:208-219.
31. Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 2008;27: 231-252.
32. Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 2006;66:3153-3161.
33. Liang F, Liang J, Wang WQ, et al. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282:5413-5419. (Pubitemid 47093772)
34. Wang H, Quah SY, Dong JM, et al. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mes-enchymal transition. Cancer Res. 2007;67:2922-2926. (Pubitemid 46724825)
35. Basak S, Jacobs SB, Krieg AJ, et al. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell. 2008;30:303-304.
36. Polato F, Codegoni A, Fruscio R, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res. 2005;11: 6835-6839. (Pubitemid 41430477)
37. Ooki A, Yamashita K, Kikuchi S, et al. Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer. BMC Cancer. 2011;11:122.